Overcoming Deadly Diseases
Phase 3 ACTION Study of ONC201 (dordaviprone) Now Enrolling
Improving and Extending Lives
Chimerix’s mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. Learn more about our approach to investing in novel drug candidates that meaningfully improve the probability of survival and the collaborative team driving the development of these promising new therapies.
ACTION Study
Chimerix Announces the initiation of the ACTION study for patients with the H3K27M mutation.
Recent Publication in Journal of Clinical Oncology
To access our most recent publication ONC201 (dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma, please click here
NEWS
- Chimerix Appoints Marc D. Kozin to Board of Directorson March 21, 2024
- Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Updateon February 29, 2024